Open Access

Epitranscriptomics of cardiovascular diseases (Review)

  • Authors:
    • Stefanos Leptidis
    • Eleni Papakonstantinou
    • Kalliopi Io Diakou
    • Katerina Pierouli
    • Thanasis Mitsis
    • Konstantina Dragoumani
    • Flora Bacopoulou
    • Despina Sanoudou
    • George P. Chrousos
    • Dimitrios Vlachakis
  • View Affiliations

  • Published online on: November 17, 2021     https://doi.org/10.3892/ijmm.2021.5064
  • Article Number: 9
  • Copyright: © Leptidis et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

RNA modifications have recently become the focus of attention due to their extensive regulatory effects in a vast array of cellular networks and signaling pathways. Just as epigenetics is responsible for the imprinting of environmental conditions on a genetic level, epitranscriptomics follows the same principle at the RNA level, but in a more dynamic and sensitive manner. Nevertheless, its impact in the field of cardiovascular disease (CVD) remains largely unexplored. CVD and its associated pathologies remain the leading cause of death in Western populations due to the limited regenerative capacity of the heart. As such, maintenance of cardiac homeostasis is paramount for its physiological function and its capacity to respond to environmental stimuli. In this context, epitranscriptomic modifications offer a novel and promising therapeutic avenue, based on the fine‑tuning of regulatory cascades, necessary for cardiac function. This review aimed to provide an overview of the most recent findings of key epitranscriptomic modifications in both coding and non‑coding RNAs. Additionally, the methods used for their detection and important associations with genetic variations in the context of CVD were summarized. Current knowledge on cardiac epitranscriptomics, albeit limited still, indicates that the impact of epitranscriptomic editing in the heart, in both physiological and pathological conditions, holds untapped potential for the development of novel targeted therapeutic approaches in a dynamic manner.

Related Articles

Journal Cover

January-2022
Volume 49 Issue 1

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Leptidis S, Papakonstantinou E, Diakou KI, Pierouli K, Mitsis T, Dragoumani K, Bacopoulou F, Sanoudou D, Chrousos GP, Vlachakis D, Vlachakis D, et al: Epitranscriptomics of cardiovascular diseases (Review). Int J Mol Med 49: 9, 2022
APA
Leptidis, S., Papakonstantinou, E., Diakou, K.I., Pierouli, K., Mitsis, T., Dragoumani, K. ... Vlachakis, D. (2022). Epitranscriptomics of cardiovascular diseases (Review). International Journal of Molecular Medicine, 49, 9. https://doi.org/10.3892/ijmm.2021.5064
MLA
Leptidis, S., Papakonstantinou, E., Diakou, K. I., Pierouli, K., Mitsis, T., Dragoumani, K., Bacopoulou, F., Sanoudou, D., Chrousos, G. P., Vlachakis, D."Epitranscriptomics of cardiovascular diseases (Review)". International Journal of Molecular Medicine 49.1 (2022): 9.
Chicago
Leptidis, S., Papakonstantinou, E., Diakou, K. I., Pierouli, K., Mitsis, T., Dragoumani, K., Bacopoulou, F., Sanoudou, D., Chrousos, G. P., Vlachakis, D."Epitranscriptomics of cardiovascular diseases (Review)". International Journal of Molecular Medicine 49, no. 1 (2022): 9. https://doi.org/10.3892/ijmm.2021.5064